Clinical trial
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
NCT00423215 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00423215 |
|---|---|
| Title | LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus |
| Official title | An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c>7% |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin glargine (LANTUS) |
| Enrollment | 1,007 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Jun 15, 2009 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: